Phase II trial of MVA 5T4 [TroVax] in combination with interferon alpha in patients with metastatic renal cancer.

Trial Profile

Phase II trial of MVA 5T4 [TroVax] in combination with interferon alpha in patients with metastatic renal cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2008

At a glance

  • Drugs Interferon alpha; MVA 5T4
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Oxford BioMedica; Sanofi
  • Most Recent Events

    • 15 Jun 2008 New trial record.
    • 02 Jun 2008 Trial results reported at American Society of Clinical Oncology annual meeting in 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top